Volume 73, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645


Myrrh (Mirazid) has been produced and marketed as an antischistosomal drug since 2001. The current study was designed to assess the efficacy of a commercially available product of myrrh. One hundred four individuals, infected with were randomized in two groups, one for myrrh and the second for praziquantel. Treatment—whether myrrh or praziquantel—was given twice with a 3-week interval. The cure rate with myrrh was very low, 15.6% after the first treatment, and 8.9% after the second treatment. Egg reduction among uncured persons was also very low, being 17.2% after the first treatment, and 28% after the second treatment. Praziquantel cure rate was 73.7% and 76.3%, and individuals still passing ova after praziquantel treatment showed a substantial reduction in the geometric mean egg counts (84% and 88.2% after the first and second treatments, respectively). When 34 individuals—uncured after two myrrh treatments—were offered praziquantel in the standard dose, 32 of them stopped passing eggs when tested 4 weeks post-treatment. The results of the current study raise serious doubts about the antischistosomal properties of Mirazid.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Hall BL, Oser BL, 1965. Progress in the consideration of flavoring ingredients under the food additive amendment. 3.GRAF substances. Food Technol 19 : 151–197.
    [Google Scholar]
  2. Ford RA, Api AM, Letizia CS, 1992. Monographs on fragrance to raw materials. Food Chem Toxicol 30 (Suppl): 91s–92s.
    [Google Scholar]
  3. Massoud A, Salama O, Bennett JL, 1998. Therapeutic efficacy of new antischistosomal drug, derived from myrrh, in active intestinal schistosomiasis complicated with hepatosplenomegaly. Proceedings of the 9th International Congress of Parasitology (ICOPA IX), Chiba, Japan. Bologna: Monduzzi Editore, Tada I, Kojima S, Tsuji M, eds., 619–623.
  4. Badria F, Abou-Mohamed G, El-Mowafy A, Masoud A, Salama O, 2001. Mirazid: a new schistosomicidal drug. Pharm Biol 39 : 127–131.
    [Google Scholar]
  5. Botros S, William S, Ebeid F, Cioli D, Katz N, Day T, Bennett J, 2004. Lack of evidence for an antischistosomal activity of myrrh in experimental animals. Am J Trop Med Hyg 71 : 206–210.
    [Google Scholar]
  6. Sheir Z, Nasr A, Massoud A, Salama O, Badra GA, El-Shennawy H, Hassan N, Hammad S, 2001. A safe and effective, herbal antischistosomal therapy derived from myrrh. Am J Trop Med Hyg 65 : 700–704.
    [Google Scholar]
  7. El Baz MA, Morsy TA, El Bandary MM, Motawea SM, 2003. Clinical and parasitological studies on the efficacy of Mirazid in treatment of schistosomiasis haematobium in Tatoon, Etsa Center, El Fayoum Governorate. J Egypt Soc Parasitol 33 : 761–767.
    [Google Scholar]
  8. Katz N, Pellegrino J, 1972. A simple device for quantitative stool thick smear technique in schistosomiasis mansoni. Rev Inst Med Trop São Paulo 14 : 397–400.
    [Google Scholar]
  9. Gryseels B, Stelma FF, Talla I, Van Dam GJ, Polman K, Sow S, Diaw M, Sturrock RF, Doehring-Schwerdtfeger E, Kardorff R, Decam C, Niag M, Deelder AM, 1994. Epidemiology, immunology and chemotherapy of Schistosoma mansoni infections in a recently exposed community in Senegal. Trop Geogr Med 46 : 209–219.
    [Google Scholar]
  10. Jordan B, Webbe G, 1982. Epidemiology. Jordan P, Webbe G, eds. Schistosomiasis, Epidemiology, Treatment and Control. London: William Heinmann Medical Books, 110–111.
  11. Utzinger J, N’Goran EK, N’Dri A, Lengeler C, Tanner M, 2000. Efficacy of praziquantel against Schistosoma mansoni with particular consideration for intensity of infection. Trop Med Int Health 5 : 771–778.
    [Google Scholar]
  12. Raso G, N’Goran EK, Toty A, Lugenbuhl A, Adjoua CA, Tian-Bi NT, Bogoch II, Vounatsou P, Tanner M, Utzinger J, 2004. Efficacy and side effects of praziquantel against Schistosoma mansoni, a community of western Cote d’Ivoire. Trans R Soc Trop Med Hyg 98 : 1–27.
    [Google Scholar]

Data & Media loading...

  • Received : 03 Sep 2004
  • Accepted : 15 Feb 2005
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error